Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
| Image |  |
|---|---|
| Description | scientific article published on 24 September 2016 |
| Author/s |
author: John Nemunaitis |
| Publication date | September 24, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |